Patent · US Active

Anti-TNF-anti-IL-17 bispecific antibodies

US9416182B2 · kind B2 · utility

2Cited by

1References

6Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

Barrett Allan · Encinitas, US
Andrew L. Glasebrook · San Diego, US
Jirong Lu · Indianapolis, US
Ying Tang · San Diego, US
Derrick Ryan Witcher · Fishers, US
Donmienne Doen Mun Leung · San Diego, US
Pia Pauliina Yachi · San Diego, US
Andrew Charles Vendel · San Diego, US

Key dates

Filing date	Mar 4, 2014
Grant date	Aug 16, 2016
Priority date	—
Expiry date	Jul 5, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNFα) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.